Goldman Sachs Said Biogen's (BIIB) BG-12 Acceptance Should Alliaate Concerns

Goldman Sachs weighed in on Biogen (NASDAQ: BIIB) Thursday after U.S. and European regulators have accepted the BG-12 for review.

The acceptance keeps the drug's timelines on track and should alleviate some
lingering investor concerns. They expect the drug to launch in early 2013.

"We continue to see significant upside in BIIB, driven by BG-12 and multiple optionalities for upside (especially Dex for ALS)," the firm said.

Goldman maintained their Buy rating and price target of $150.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed are up 1 percent mid-day Thursday to $133.89.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS